Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia
Sylvie Castaigné, Philippe Lefèbvre, Christine Chomienne et al. · Blood · 1993
It has been shown that all-trans retinoic acid (ATRA) at doses of 45 to 100 mg/m2/d induces complete remission (CR) of acute promyelocytic leukemia (APL) by a differentiation process. To date, ATRA dose-ranging studies have not yet been evaluated. Thus, we initiated in May 1990 a multicenter study with ATRA at a lower dose of 25 mg/m2/d until CR. Thirty patients with APL were treated with ATRA, of whom 12 were previously untreated, 14 were in first relapse, and 4 had failed after conventional first induction chemotherapy. Twenty-four of 30 achieved CR, 3 failed, and 3 died before day 30. Median time to CR was 45 days. Hyperleucocytosis (14 to 43 x 10(9) white blood cells per liter) was observed in 9 patients between days 10 and 23. Clinical complications that may have been related to the retinoic acid syndrome were observed in 8 patients, of whom 3 died. Pharmacokinetics studies were performed in 5 patients. Peak plasma concentrations and mean area under the concentration-time curve were not lower than previous levels obtained under the 45 mg/m2 dose. Overall, our study shows that there is no difference in terms of therapeutic efficacy, triggering of hyperleukocytosis, or retinoic acid syndrome and pharmacokinetic results with ATRA at 25 or 45 mg/m2/d.
Cited by 104 works. doi:10.1182/blood.v82.12.3560.3560
Authors
- Sylvie Castaigné
- Philippe Lefèbvre
- Christine Chomienne
- Etienne Suc
- Françoise Huguet
- Claude Gardin
- Alain Jacques Delmer
- Eric Archimbaud
- Hervé Tilly
- Maud Janvier
References
- Proposals for the Classification of the Acute Leukaemias F rench ‐A merican ‐B ritish (FAB) C o‐operative G roup
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
- The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
- All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results [see comments]
- Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia
- A VARIANT FORM OF HYPERGRANULAR PROMYELOCYTIC LEUKAEMIA (M3)
- The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia
- All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship
- A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients